Personalized Cancer Monitoring News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Natera offers Invitae $52 5M for prenatal screening tests

Natera offers Invitae $52 5M for prenatal screening tests
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Ken knightPersonalized cancer monitoringNew york stock exchangeAnchored multiplex

Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics RaDaR Test -December 27, 2023 at 11:49 pm EST

Order enjoins NeoGenomics from making, using, selling or promoting its RaDaR molecular residual disease assay in the United States with limited exceptions .

United statesNorth carolinaSan carlosDelaware federal district courtClinical laboratory improvement amendmentsInvitae corporationDistrict courtNeogenomics labs incNatera incMiddle districtNeogenomics labsNeogenomics radarPersonalized cancer monitoring

Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics RaDaR Test

Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics RaDaR Test
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan carlosNorth carolinaLesley bogdanowMike brophyClinical laboratory improvement amendmentsNatera incDistrict courtNeogenomics labs incDelaware federal district courtCorporate communicationsInvitae corporationMiddle districtNeogenomics labsNeogenomics radarPersonalized cancer monitoring

US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In Lawsuit - Natera (NASDAQ:NTRA), NeoGenomics (NASDAQ:NEO)

Shares of NeoGenomics Inc (NASDAQ: NEO) fell Thursday after the company received a preliminary injunction from a North Carolina district court, which prohibits the company from 

United statesNorth carolinaWilliam blairNatera incInvitae corporationNeogenomics incClinical servicesDelaware federal district courtNeogenomic radarNeogenomics radarPersonalized cancer monitoringAdvanced diagnostics

Natera strengthens IP position with Archerdx win

On Dec. 1, a judge in the U.S. District Court for the District of Delaware granted Natera Inc. a permanent injunction in its patent infringement suit against Archerdx Inc. and its former parent company, Invitae Corp., adding another block to the intellectual property wall of protection around the market dominance of Signatera, Natera’s molecular residual disease (MRD) assay.

United statesUs district courtNatera incInvitae corpArcherdx incGuardant health incTwinstrand therapeutics incMolecular residual diseaseNatera incDanaher corpInvitae corpArcherdx incLiquid biopsyPersonalized cancer monitoring